The FDA Approved Rhythm Pharmaceuticals Product IMCIVREE™ for Genetic Obesity due to POMC, PCSK1 or LEPR Deficiency

Rhythm Pharmaceuticals FDA Approval of IMCIVREE™ for Genetic Obesity
At the end of the trading week last Friday, November 27, 2020, the United States FDA approved Rhythm Pharmaceuticals’ (RYTM) product IMCIVREE™ (setmelanotide). The product is designed to treat chronic obese adult patients and pediatric patients 6 years and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/Kexin type . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.